News Early Clovis approval notches up competition in ovarian canc... Clovis' Rubraca will compete against AstraZeneca rival.
News Clovis takes stock as rival Tesaro shines Oncology firm could make acquisition if ovarian cancer drug approved.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
